Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT06461988
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talquetamab — DRUG
    Talquetamab Step up dosing: C1D1: 10 mcg/kg C1D3: 60 mcg/kg C1D5: 400 mcg/kg C1D15: 800 mcg/kg Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13
  • Talquetamab and Lenalidomide — DRUG
    Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)

Study Details

Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

Key Dates

Start date
Jun 5, 2025
Status verified
Aug 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Talquetamab
    Study participants will receive talquetamab (JNJ-64407564) for one cycle and a combination of talquetamab and lenalidomide for cycles 2-13 after autologous stem cell transplant (ASCT).

Primary Outcome Measure

Stringent Complete Response (sCR) + Complete Response (CR) Rate [ Time Frame: 12 months after the start of talquetamab in each participant. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94304
Brent LaStofka
[email protected]
650-922-0868
Surbhi Sidana, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Stanford University· Palo Alto, CA

Related Studies